FDA initiates pilot program for evaluating AI-designed drugs
Over 200 drugs developed using artificial intelligence are currently in clinical trials around the world. To date, none have received FDA approval.
The Food and Drug Administration has introduced a pilot initiative aimed at determining how to assess AI-generated evidence in drug applications. Ten companies have been selected for an accelerated, interactive review process.
Development in the AI pharmaceutical sector has progressed more rapidly than existing regulatory guidelines. This situation now defines the state of AI-driven drug development.
We've been having a lot of fun testing AI recently in a brand and web projects.
I'm a big believer in everything we produce is human first and AI assisted to help spin up ideas of enhance our digital presence. Behind the scenes there isn't anything we can't achieve in digital now.
With Claude 5.5, An initial brief and just a few prompts later on a logo animation and I can visualise what I want for my animators and not just have to talk them through a few slides.
Most will say do we even need to improve what claude spits out, but I notice the little things and the little things are why we are always busy.
But this unlock has huge potential for us and our clients.
Parallel, the fund site set like a quarterly journal, now has a @Framer edition.
Native sections, CMS letters and companies with their own pages, the inked essay and figures as code components, and five Framer Skills for Framer's agent. It's the fourth template on Framer, after Oda, Signal and Tender.